Intensity Therapeutics Common Stock Technical Analysis
| INTS Stock | 0.25 0.12 32.43% |
As of the 14th of February 2026, Intensity Therapeutics retains the Standard Deviation of 7.92, market risk adjusted performance of (0.21), and Risk Adjusted Performance of (0.04). Intensity Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Intensity Therapeutics risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Intensity Therapeutics is priced fairly, providing market reflects its last-minute price of 0.25 per share. As Intensity Therapeutics appears to be a penny stock we also urge to confirm its jensen alpha numbers.
Intensity Therapeutics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Intensity, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to IntensityIntensity | Build AI portfolio with Intensity Stock |
Intensity Therapeutics Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 2.9 | Buy | 5 | Odds |
Most Intensity analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Intensity stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Intensity Therapeutics, talking to its executives and customers, or listening to Intensity conference calls.
Is there potential for Biotechnology market expansion? Will Intensity introduce new products? Factors like these will boost the valuation of Intensity Therapeutics. Market participants price Intensity higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Intensity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Intensity Therapeutics is measured differently than its book value, which is the value of Intensity that is recorded on the company's balance sheet. Investors also form their own opinion of Intensity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intensity Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Intensity Therapeutics' market value can be influenced by many factors that don't directly affect Intensity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intensity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intensity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Intensity Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Intensity Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Intensity Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Intensity Therapeutics.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Intensity Therapeutics on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Intensity Therapeutics Common or generate 0.0% return on investment in Intensity Therapeutics over 90 days. Intensity Therapeutics is related to or competes with Iterum Therapeutics, Rallybio Corp, IBio Common, Pluri, Boundless Bio, Plus Therapeutics, and NextCure. Intensity Therapeutics is entity of United States More
Intensity Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Intensity Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Intensity Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 51.11 | |||
| Value At Risk | (10.64) | |||
| Potential Upside | 11.43 |
Intensity Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Intensity Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Intensity Therapeutics' standard deviation. In reality, there are many statistical measures that can use Intensity Therapeutics historical prices to predict the future Intensity Therapeutics' volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.60) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | (0.22) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Intensity Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intensity Therapeutics February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.21) | |||
| Mean Deviation | 4.88 | |||
| Coefficient Of Variation | (1,713) | |||
| Standard Deviation | 7.92 | |||
| Variance | 62.66 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.60) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | (0.22) | |||
| Maximum Drawdown | 51.11 | |||
| Value At Risk | (10.64) | |||
| Potential Upside | 11.43 | |||
| Skewness | (0.11) | |||
| Kurtosis | 6.81 |
Intensity Therapeutics Backtested Returns
Intensity Therapeutics holds Efficiency (Sharpe) Ratio of -0.0777, which attests that the entity had a -0.0777 % return per unit of risk over the last 3 months. Intensity Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Intensity Therapeutics' Market Risk Adjusted Performance of (0.21), risk adjusted performance of (0.04), and Standard Deviation of 7.92 to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 2.14, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Intensity Therapeutics will likely underperform. At this point, Intensity Therapeutics has a negative expected return of -0.54%. Please make sure to check out Intensity Therapeutics' maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and period momentum indicator , to decide if Intensity Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.06 |
Virtually no predictability
Intensity Therapeutics Common has virtually no predictability. Overlapping area represents the amount of predictability between Intensity Therapeutics time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Intensity Therapeutics price movement. The serial correlation of 0.06 indicates that barely 6.0% of current Intensity Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.06 | |
| Spearman Rank Test | -0.14 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Intensity Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Intensity Therapeutics Technical Analysis
The output start index for this execution was one with a total number of output elements of sixty. The Normalized Average True Range is used to analyze tradable apportunities for Intensity Therapeutics across different markets.
About Intensity Therapeutics Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Intensity Therapeutics Common on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Intensity Therapeutics Common based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Intensity Therapeutics price pattern first instead of the macroeconomic environment surrounding Intensity Therapeutics. By analyzing Intensity Therapeutics's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Intensity Therapeutics's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Intensity Therapeutics specific price patterns or momentum indicators. Please read more on our technical analysis page.
Intensity Therapeutics February 14, 2026 Technical Indicators
Most technical analysis of Intensity help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Intensity from various momentum indicators to cycle indicators. When you analyze Intensity charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.21) | |||
| Mean Deviation | 4.88 | |||
| Coefficient Of Variation | (1,713) | |||
| Standard Deviation | 7.92 | |||
| Variance | 62.66 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.60) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | (0.22) | |||
| Maximum Drawdown | 51.11 | |||
| Value At Risk | (10.64) | |||
| Potential Upside | 11.43 | |||
| Skewness | (0.11) | |||
| Kurtosis | 6.81 |
Intensity Therapeutics February 14, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Intensity stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.14 | ||
| Daily Balance Of Power | (3.00) | ||
| Rate Of Daily Change | 0.68 | ||
| Day Median Price | 0.27 | ||
| Day Typical Price | 0.26 | ||
| Price Action Indicator | (0.08) | ||
| Market Facilitation Index | 0.04 |
Additional Tools for Intensity Stock Analysis
When running Intensity Therapeutics' price analysis, check to measure Intensity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intensity Therapeutics is operating at the current time. Most of Intensity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intensity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intensity Therapeutics' price. Additionally, you may evaluate how the addition of Intensity Therapeutics to your portfolios can decrease your overall portfolio volatility.